Nucs AI and AstraZeneca Partner on AI Models for Prostate Cancer Research

Nucs AI, an AI company developing diagnostic tools and predictive imaging biomarkers for oncology and theranostics, announced a collaboration with AstraZeneca to develop AI-driven response prediction models for use in research with a PSMA-targeted radioconjugate. The collaboration focuses on metastatic prostate cancer and reflects a growing recognition that predictive imaging-based biomarkers may play a meaningful role in how precision oncology therapies are optimized.

Under the collaboration, Nucs AI will adapt and validate a product for emerging radioconjugates in metastatic castration-resistant prostate cancer. The work centers on tuning response-prediction models to the specific characteristics of next-generation therapies, drawing on the platform's foundation in Lutetium-based therapy response predictions. By advancing predictive biomarker development in parallel with AstraZeneca, the collaboration positions AI-driven response prediction to mature in step with the therapies it is designed to support.

"For Nucs AI, the collaboration with AstraZeneca anchors a broader strategic ambition: building a precision medicine engine, a platform for identifying and developing predictive imaging biomarker models across existing and novel therapies. This approach scales beyond a single therapy class or cancer type, extending over time across additional treatment modalities, disease contexts, and therapeutic targets," said Nijat Ahmadov, CEO of Nucs AI. "Nuclear oncology, where imaging-derived biomarkers connect directly to treatment selection, is the natural starting point."